We have delighted initiated the larger Phase 2b study with the lead compound 444 in COPD.

‘We have delighted initiated the larger Phase 2b study with the lead compound ‘444 in COPD, ‘said Rick E Winningham, Chief Executive Officer of Theravance. ‘With ‘444 now in large Phase 2b studies of both asthma and COPD, we have two major goals, which meets to bring us closer to our common goal, a new treatment option for patients in these major therapeutic areas. ‘.

THERAVANC, the Theravance logo, and differenc making a differenc registered trademarks of Theravance,GlaxoSmithKline pioneering atatementsUnder the safe harbor provisions of the U.S. Factors that could affect the Group’s operations under under ‘Risk Factors’ on the business and prospects of the Company Annual Report on Form 20-F for the year 2006.Courtesy can total daily Women’s Health Policy Reports display, search the archives and sign up for email Shipping here to reprint the everyday Women’s Health Policy. Report is a free service of the National Partnership for Women & Families.

Other Posts From Category "sexology":

Related Posts